The association of post-stroke anhedonia with salivary cortisol levels and stroke lesion in hippocampal/parahippocampal region

Carregando...
Imagem de Miniatura
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
DOVE MEDICAL PRESS LTD
Citação
Neuropsychiatric Disease and Treatment, v.11, p.233-242, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Anhedonia constitutes a coherent construct, with neural correlates and negative clinical impact, independent of depression. However, little is known about the neural correlates of anhedonia in stroke patients. In this study, we investigated the association of post-stroke anhedonia with salivary cortisol levels and stroke location and volume. Patients and methods: A psychiatrist administered the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition to identify anhedonia in 36 inpatients, without previous depression, consecutively admitted in a neurology clinic in the first month after a first-ever ischemic stroke. Salivary cortisol levels were assessed in the morning, evening, and after a dexamethasone suppression test. We used magnetic resonance imaging and a semi-automated brain morphometry method to assess stroke location, and the MRIcro program according to the Brodmann Map to calculate the lesion volume. Results: Patients with anhedonia had significantly larger diurnal variation (P-value =0.017) and higher morning levels of salivary cortisol (1,671.9 +/- 604.0 ng/dL versus 1,103.9 +/- 821.9 ng/dL; P-value =0.022), and greater stroke lesions in the parahippocampal gyrus (Brodmann area 36) compared to those without anhedonia (10.14 voxels; standard deviation +/- 17.72 versus 0.86 voxels; standard deviation +/- 4.64; P-value =0.027). The volume of lesion in the parahippocampal gyrus (Brodmann area 36) was associated with diurnal variation of salivary cortisol levels (rho=0.845; P-value =0.034) only in anhedonic patients. Conclusion: Our findings suggest that anhedonia in stroke patients is associated with the volume of stroke lesion in the parahippocampal gyrus and with dysfunction of the hypothalamic-pituitary-adrenal axis.
Palavras-chave
anhedonia, stroke, glucocorticoids, depression, hippocampus, parahippocampal
Referências
  1. Abercrombie HC, 2011, J PSYCHIATR RES, V45, P15, DOI 10.1016/j.jpsychires.2010.10.005
  2. Abramovitch A, 2014, PSYCHIAT RES, V216, P223, DOI 10.1016/j.psychres.2014.02.002
  3. Aihara M, 2007, PSYCHIAT RES-NEUROIM, V155, P245, DOI 10.1016/j.pscychresns.2006.11.002
  4. Almeida JRC, 2009, PSYCHIAT RES-NEUROIM, V174, P195, DOI 10.1016/j.pscychresns.2009.04.015
  5. American Psychiatric Association, 2013, DIAGN STAT MAN MENT
  6. Appelhof BC, 2006, BIOL PSYCHIAT, V59, P696, DOI 10.1016/j.biopsych.2005.09.008
  7. ASTROM M, 1993, STROKE, V24, P52
  8. Barugh AJ, 2014, J NEUROL, V261, P533, DOI 10.1007/s00415-013-7231-5
  9. Bhogal SK, 2004, STROKE, V35, P794, DOI 10.1161/01.STR.0000117237.98749.26
  10. Brodaty H, 2005, PSYCHOL MED, V35, P1707, DOI 10.1017/S0033291705006173
  11. BROTT T, 1989, STROKE, V20, P864
  12. Brouwer JP, 2006, PSYCHONEUROENDOCRINO, V31, P1154, DOI 10.1016/j.psyneuen.2006.08.001
  13. Carson AJ, 2000, LANCET, V356, P122, DOI 10.1016/S0140-6736(00)02448-X
  14. Castro M, 1999, J CLIN ENDOCR METAB, V84, P878, DOI 10.1210/jc.84.3.878
  15. Chase HW, 2010, PSYCHOL MED, V40, P433, DOI 10.1017/S0033291709990468
  16. Cincura C, 2009, CEREBROVASC DIS, V27, P119, DOI 10.1159/000177918
  17. Clarke David M, 2005, World Psychiatry, V4, P96
  18. Covinsky KE, 2014, AM J GERIAT PSYCHIAT, V22, P606, DOI 10.1016/j.jagp.2012.12.001
  19. Crespo-Facorro B, 2001, JAMA-J AM MED ASSOC, V286, P427, DOI 10.1001/jama.286.4.427
  20. Davidson KW, 2010, ARCH GEN PSYCHIAT, V67, P480, DOI 10.1001/archgenpsychiatry.2010.36
  21. Palacios RDY, 2011, BIOL PSYCHIAT, V70, P449, DOI 10.1016/j.biopsych.2011.05.014
  22. de Quervain DJF, 2003, EUR J NEUROSCI, V17, P1296, DOI 10.1046/j.1460-9568.2003.02542.x
  23. Dougherty LR, 2009, J CHILD PSYCHOL PSYC, V50, P1495, DOI 10.1111/j.1469-7610.2009.02116.x
  24. Drevets WC, 2008, BRAIN STRUCT FUNCT, V213, P93, DOI 10.1007/s00429-008-0189-x
  25. EVANS AC, 1993, NUCLEAR SCIENCE SYMPOSIUM & MEDICAL IMAGING CONFERENCE, VOLS 1-3, P1813
  26. Farner L, 2009, INT J GERIATR PSYCH, V24, P1209, DOI 10.1002/gps.2247
  27. FASSBENDER K, 1994, STROKE, V25, P1105
  28. FEIBEL JH, 1977, JAMA-J AM MED ASSOC, V238, P1374, DOI 10.1001/jama.238.13.1374
  29. First MB, 1995, STRUCTURED CLIN INTE
  30. Fraguas Renerio Jr, 2002, Rev Assoc Med Bras, V48, P225, DOI 10.1590/S0104-42302002000300035
  31. Furlanetto LM, 2000, PSYCHOSOMATICS, V41, P426, DOI 10.1176/appi.psy.41.5.426
  32. Gabbay V, 2012, ARCH GEN PSYCHIAT, V69, P139, DOI 10.1001/archgenpsychiatry.2011.131
  33. Goldstein KE, 2009, SCHIZOPHR RES, V112, P14, DOI 10.1016/j.schres.2009.04.027
  34. Grool AM, 2012, PSYCHOL MED, V42, P359, DOI 10.1017/S0033291711001383
  35. Hasler G, 2008, ARCH GEN PSYCHIAT, V65, P521, DOI 10.1001/archpsyc.65.5.521
  36. Herbert J, 2013, PSYCHOL MED, V43, P449, DOI 10.1017/S0033291712000955
  37. Hinkelmann K, 2009, BIOL PSYCHIAT, V66, P879, DOI 10.1016/j.biopsych.2009.06.023
  38. Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7
  39. Hyett MP, 2008, J AFFECT DISORDERS, V109, P193, DOI 10.1016/j.jad.2007.11.005
  40. Insel TR, 2009, ARCH GEN PSYCHIAT, V66, P128, DOI 10.1001/archgenpsychiatry.2008.540
  41. Johansson A, 1997, J NEUROL SCI, V147, P43
  42. Juruena MF, 2013, J PSYCHOPHARMACOL, V27, P1169, DOI 10.1177/0269881113499205
  43. Keating C, 2012, NEUROPSYCHOLOGIA, V50, P567, DOI 10.1016/j.neuropsychologia.2012.01.036
  44. Keedwell PA, 2005, BIOL PSYCHIAT, V58, P843, DOI 10.1016/j.biophysh.2005.05.019
  45. Krishnan KRR, 1997, AM J PSYCHIAT, V154, P497
  46. Lavretsky H, 2008, INT J GERIATR PSYCH, V23, P1040, DOI 10.1002/gps.2030
  47. Leventhal AM, 2008, AM J ADDICTION, V17, P218, DOI 10.1080/10550490802019774
  48. MAHONEY F I, 1965, Md State Med J, V14, P61
  49. Martiny K, 2009, ACTA PSYCHIAT SCAND, V120, P196, DOI 10.1111/j.1600-0447.2009.01359.x
  50. Mead G, 2007, STROKE, V38, P2090, DOI 10.1161/STROKEAHA.106.478941
  51. Miller G, 2010, SCIENCE, V327, P1437, DOI 10.1126/science.327.5972.1437
  52. Monkul ES, 2012, HUM BRAIN MAPP, V33, P272, DOI 10.1002/hbm.21212
  53. Montag C, 2009, PSYCHOL MED, V39, P1831, DOI 10.1017/S0033291709005509
  54. Murakami T., 2013, PSYCHIATRY, V21, P840
  55. MURROS K, 1993, J NEUROL SCI, V116, P12, DOI 10.1016/0022-510X(93)90083-B
  56. Narushima K, 2003, J NEUROPSYCH CLIN N, V15, P422, DOI 10.1176/appi.neuropsych.15.4.422
  57. OLSSON T, 1992, STROKE, V23, P1573
  58. OLSSON T, 1989, STROKE, V20, P1685
  59. Papoiu ADP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082389
  60. Pariante CM, 2009, ANN NY ACAD SCI, V1179, P144, DOI 10.1111/j.1749-6632.2009.04978.x
  61. Pelle AJ, 2011, QUAL LIFE RES, V20, P643, DOI 10.1007/s11136-010-9792-4
  62. Pfeiffer PN, 2014, J AFFECT DISORDERS, V152, P277, DOI 10.1016/j.jad.2013.09.025
  63. PIAMARTA F, 2004, ARCH GERONTOLOGY G S, V9, P315
  64. Pizzagalli DA, 2014, ANNU REV CLIN PSYCHO, V10, P393, DOI 10.1146/annurev-clinpsy-050212-185606
  65. Pizzagalli DA, 2009, AM J PSYCHIAT, V166, P702, DOI 10.1176/appi.ajp.2008.08081201
  66. Pringle A, 2013, J PSYCHOPHARMACOL, V27, P719, DOI 10.1177/0269881112474523
  67. Putnam KM, 2008, PSYCHOPHYSIOLOGY, V45, P886, DOI 10.1111/j.1469-8986.2008.00697.x
  68. Quaranta D, 2012, BEHAV NEUROL, V25, P303, DOI 10.3233/BEN-2012-110236
  69. Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925
  70. Sheline YI, 2000, BIOL PSYCHIAT, V48, P791, DOI 10.1016/S0006-3223(00)00994-X
  71. Shelton RC, 2001, PSYCHIATR SERV, V52, P1469, DOI 10.1176/appi.ps.52.11.1469
  72. Sibitz I, 2010, J AFFECT DISORDERS, V126, P245, DOI 10.1016/j.jad.2010.03.023
  73. Sibon I, 2012, CEREBROVASC DIS, V33, P280, DOI 10.1159/000334663
  74. Silva CEDE, 2013, CEREBROVASC DIS, V35, P385, DOI 10.1159/000348852
  75. Soriano-Mas C, 2011, BIOL PSYCHIAT, V69, P318, DOI 10.1016/j.biopsych.2010.07.029
  76. Spijker J, 2001, ACTA PSYCHIAT SCAND, V103, P122, DOI 10.1034/j.1600-0447.2001.103002122.x
  77. Stetler C, 2011, PSYCHOSOM MED, V73, P114, DOI 10.1097/PSY.0b013e31820ad12b
  78. Stroke-Recommendations on stroke prevention diagnosis and therapy, 1989, STROKE, V20, P1407
  79. Talairach J, 1988, COPLANAR STEREOTAXIC
  80. Tang WK, 2013, CEREBROVASC DIS, V35, P566, DOI 10.1159/000351152
  81. Tchanturia K, 2012, INT J EAT DISORDER, V45, P962, DOI 10.1002/eat.22032
  82. Terroni L, 2011, WORLD J BIOL PSYCHIA, V12, P539, DOI 10.3109/15622975.2011.562242
  83. Terroni LDN, 2009, REV BRAS PSIQUIATR, V31, P202, DOI 10.1590/S1516-44462009000300004
  84. Treadway MT, 2011, NEUROSCI BIOBEHAV R, V35, P537, DOI 10.1016/j.neubiorev.2010.06.006
  85. Turkcapar MH, 1999, J AFFECT DISORDERS, V54, P101, DOI 10.1016/S0165-0327(98)00146-3
  86. Vaisvaser S, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00313
  87. van Dalen JW, 2013, STROKE, V44, P851, DOI 10.1161/STROKEAHA.112.674614
  88. Van Essen DC, 1998, P NATL ACAD SCI USA, V95, P788, DOI 10.1073/pnas.95.3.788
  89. Vataja R, 2004, J NEUROPSYCH CLIN N, V16, P156, DOI 10.1176/appi.neuropsych.16.2.156
  90. Vataja R, 2001, ARCH GEN PSYCHIAT, V58, P925, DOI 10.1001/archpsyc.58.10.925
  91. Velthorst E, 2012, SCHIZOPHR RES, V138, P290, DOI 10.1016/j.schres.2012.03.022
  92. Wacker J, 2009, NEUROIMAGE, V46, P327, DOI 10.1016/j.neuroimage.2009.01.058
  93. Wang SH, 2009, PSYCHIAT RES, V170, P245, DOI 10.1016/j.psychres.2008.07.006
  94. Wang SH, 2010, PHARMACOL BIOCHEM BE, V95, P129, DOI 10.1016/j.pbb.2009.12.017
  95. Yu Lifa, 2004, Kaohsiung Journal of Medical Sciences, V20, P372
  96. Zimmerman M, 2013, J CLIN PSYCHIAT, V74, P470, DOI 10.4088/JCP.12m08053